492,900 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Bought by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 492,900 shares of the biopharmaceutical company's stock, valued at approximately $4,288,000. Polar Asset Management Partners Inc. owned approximately 0.32% of Ocular Therapeutix as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Atlas Capital Advisors LLC purchased a new position in Ocular Therapeutix during the 2nd quarter valued at about $34,000. Amalgamated Bank boosted its holdings in shares of Ocular Therapeutix by 37.9% during the second quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company's stock worth $37,000 after purchasing an additional 1,481 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Ocular Therapeutix by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 1,015 shares in the last quarter. Algert Global LLC acquired a new position in Ocular Therapeutix in the 2nd quarter valued at approximately $69,000. Finally, Capital Performance Advisors LLP acquired a new position in Ocular Therapeutix in the 3rd quarter valued at approximately $70,000. Institutional investors and hedge funds own 59.21% of the company's stock.

Ocular Therapeutix Stock Down 3.2 %

Shares of NASDAQ:OCUL traded down $0.30 on Thursday, reaching $9.18. The company had a trading volume of 721,733 shares, compared to its average volume of 1,814,566. The stock has a market capitalization of $1.44 billion, a P/E ratio of -6.95 and a beta of 1.19. The stock has a 50-day moving average price of $10.04 and a 200 day moving average price of $8.34. Ocular Therapeutix, Inc. has a twelve month low of $3.24 and a twelve month high of $11.77. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Scotiabank initiated coverage on shares of Ocular Therapeutix in a report on Wednesday, October 16th. They set a "sector outperform" rating and a $22.00 price target on the stock. Robert W. Baird lowered their target price on Ocular Therapeutix from $18.00 to $17.00 and set an "outperform" rating on the stock in a research note on Thursday, August 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of Ocular Therapeutix in a research note on Tuesday. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $16.71.

Insider Activity at Ocular Therapeutix

In related news, insider Jeffrey S. Heier sold 2,948 shares of the business's stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $9.01, for a total transaction of $26,561.48. Following the completion of the transaction, the insider now owns 269,059 shares of the company's stock, valued at approximately $2,424,221.59. The trade was a 1.08 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.50% of the stock is owned by company insiders.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.